Kingmed Diagnostics(SH:603882) Xin Lang Cai Jing·2025-11-28 02:05Core Viewpoint - The stock of Kingmed Diagnostics has shown a mixed performance in recent trading sessions, with a year-to-date increase of 12.08% but a decline over the past 60 days [1][2]. Company Overview - Kingmed Diagnostics, established on May 26, 2006, and listed on September 8, 2017, is based in Guangzhou, China. The company provides a wide range of diagnostic services to over 23,000 medical institutions across the country, covering nearly 80 types of testing technologies and approximately 3,200 testing projects [1]. - The main revenue sources for the company include: medical diagnostic services (91.20%), sales of diagnostics (6.45%), other services (1.47%), cold chain logistics (0.62%), and health check services (0.27%) [1]. Financial Performance - For the period from January to September 2025, Kingmed Diagnostics reported a revenue of 4.538 billion yuan, a year-on-year decrease of 19.23%. The net profit attributable to the parent company was -796.095 million yuan, reflecting a significant decline of 184.84% compared to the previous year [2]. - Since its A-share listing, the company has distributed a total of 2.545 billion yuan in dividends, with 1.647 billion yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Kingmed Diagnostics was 41,700, a decrease of 1.60% from the previous period. The average number of tradable shares per shareholder increased by 1.62% to 11,042 shares [2]. - The top circulating shareholder, Hong Kong Central Clearing Limited, held 35.5057 million shares, a reduction of 2.8676 million shares from the previous period. The eighth largest shareholder, Hua Bao Zhong Zheng Medical ETF, held 7.8786 million shares, down by 1.2515 million shares [3].